Hey there!

It’s Sparsh here!👋 

Medical imaging is a cornerstone of modern healthcare, yet millions still lack timely, accurate diagnostics, especially in countries like India, where radiologists are scarce. As AI transforms industries worldwide, its role in medical imaging promises faster, scalable, and more affordable solutions. 💉 

Understanding how companies like Qure.ai are leveraging advanced algorithms, regulatory leadership, and global partnerships is key to grasping the future of AI-driven diagnostics. 🔑 

Let’s dive in to know more! 🚀 

Table of Contents

• 🔎Setting the Stage

• ⚡Quick Take

• 📌Core Insights

• 🔍 Behind the Strategy

• 👥 Meet the Makers

CONTEXT
🔎Setting the Stage

1. The global medical imaging market is projected to grow from about USD 49.61 billion in 2024 to USD 80.52 billion by 2034. CAGR stands at 4.96%.📈 

2. AI in medical imaging is expanding even faster. It’s expected to surge from USD 1.36 billion in 2024 to USD 19.78 billion by 2033. That’s a CAGR of 34.67%. 🤖

3. AI adoption in Indian healthcare faces hurdles: fragmented data, infrastructure gaps, and low physician trust. But new regulations and digital health push innovation forward. 🔍

4. India’s burden of TB, lung cancer, and heart conditions demands early, affordable, scalable diagnostics to save lives and cut costs. 🪙 

⚡Quick Take

COMPANY BACKGROUND
📌Core Insights

• 🌏Headquarters: Mumbai, India

• 👥Core Team: 2

• 💼Business Model: B2B SaaS. It licenses its AI solutions to hospitals, diagnostic centres, governments, and public health programs; it also partners with global health organisations for large-scale screening initiatives.

• 🏢Founded: 2016

• 📈Traction: 

  • Raised $123 million over 8 rounds, including a $65 million Series D in September 2024. Key investors include Lightspeed Venture Partners, Merck Global Health Innovation Fund, etc. 📜 

  • Deployed in 3,100+ sites, processed over 25 million scans, and reached 25 million people globally📱 

🔍 Behind the Strategy

🤔What’s Exciting?

• Market Opportunity📊: AI medical imaging is booming with a global CAGR of 34.67% and 38.1% in India. Qure.ai sits right at this intersection.

• Regulatory Leadership📜: Holds 18 FDA clearances, most for lung cancer AI, plus CE certifications for global trust.

• Product Innovation💡: Tools like qXR, qXR-LN, and qXR-BT automate scans and boost accuracy.

🤔What’s Risky?

• Adoption Barriers 🚧: AI adoption in Indian healthcare faces challenges, including fragmented data, limited infrastructure, and physician resistance due to a lack of training and trust in AI systems.

• Regulatory Complexity🏦 : Navigating India’s evolving regulatory landscape, CDSCO, Digital Personal Data Protection Act, and new clinical trial rules requires ongoing compliance and adaptation.

• Data Privacy and Ethics 🔏: Ensuring patient data privacy, addressing bias in AI models, and maintaining transparency are ongoing challenges, especially as Qure.ai scales across diverse geographies.

👥 Meet the Leaders

Prashant Warier | Pooja Rao